ENGLISH
CBS2017
Previous Next
Home < 科学研究

搜索结果

数量：1763 条

排序

Refine search

Influence of Local Myocardial Damage on Index of Microcirculatory Resistance and Fractional Flow Reserve in Target and Nontarget Vascular Territories in a Porcine Microvascular Injury Model

Original Research | By JM Lee, HK Kim, KS Lim et al.

OBJECTIVES - The aim of this study was to investigate the influence of microvascular damage in one vessel territory on invasively measured physiological parameters in the other vessel, using a porcine microvascular damage model. BACKGROUND - Although fractional flow reserve (FFR)-guided decision-making for the nonculprit stenosis in patients with acute myocardial infarction has been reported to be better than angi...

6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial

Original Research | By Hahn JY, Song YB, SMART-DATE investigators et al.

BACKGROUND - Current guidelines recommend dual antiplatelet therapy (DAPT) of aspirin plus a P2Y12 inhibitor for at least 12 months after implantation of drug-eluting stents (DES) in patients with acute coronary syndrome. However, available data about the optimal duration of DAPT in patients with acute coronary syndrome undergoing percutaneous coronary intervention are scant. We aimed to investigate whether a 6-month duration...

A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial

Clinical Trial | By de Winter RJ, Katagiri Y, Serruys PW et al.

BACKGROUND - MiStent is a drug-eluting stent with a fully absorbable polymer coating containing and embedding a microcrystalline form of sirolimus into the vessel wall. It was developed to overcome the limitation of current durable polymer drug-eluting stents eluting amorphous sirolimus. The clinical effect of MiStent sirolimus-eluting stent compared with a durable polymer drug-eluting stents has not been investigated in a large random...

Effect of Side Branch Predilation in Coronary Bifurcation Stenting With the Provisional Approach - Results From the COBIS (Coronary Bifurcation Stenting) II Registry

Original Research | By Lee SH, Song YB, Lee JM et al.

BACKGROUND - Whether side branch (SB) predilation before main vessel (MV) stenting is beneficial is uncertain, so we investigated the effects of SB predilation on procedural and long-term outcomes in coronary bifurcation lesions treated using the provisional approach.Methods and Results:A total of 1,083 patients with true bifurcation lesions undergoing percutaneous coronary intervention were evaluated. The primary outcome was a ma...

The Wait for High-Sensitivity Troponin Is Over—Proceed Cautiously

Expert Opinion | By Korley FK

Since high-sensitivity troponin (hsTn) assays became available for clinical use in Europe in 2010, clinicians in the United States have been waiting eagerly for US Food and Drug Administration (FDA) approval. It is finally here. High-sensitivity troponin assays hold promise for earlier diagnosis of myocardial infarction (MI), a decrease in the time required to rule out MI, a reduction in sex bias in the diagnosis of MI, and an improvement ...

Impact of the US Food and Drug Administration–Approved Sex-Specific Cutoff Values for High-Sensitivity Cardiac Troponin T to Diagnose Myocardial Infarction

Expert Opinion | By MR Gimenez, P Badertscher, R Twerenbold et al.

In patients presenting with suspected myocardial infarction (MI), beyond the presence or absence of MI, 4 clinical variables seem to affect high-sensitivity cardiac troponin (hs-cTn) concentrations: age, renal dysfunction, time from chest pain onset, and sex.1 Among the 4 variables, sex has received the most attention, resulting in uncertainty about the need to abandon the 1 overall cutoff in favor of sex-specific cutoffs for hs-cTn in the diagnosis of...

Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial

Clinical Trial | By Giugliano RP, Keech A, Murphy SA et al.

IMPORTANCE - Current guidelines for atherosclerotic cardiovascular disease focus on high-intensity statins and targeting or using a threshold low-density lipoprotein cholesterol (LDL-C) level of less than 70 mg/dL for the highest-risk patients. Whether further reduction of LDL-C beyond these boundaries would be beneficial is unknown. OBJECTIVE - To compare outcomes of evolocumab vs placebo in patients ...

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Original Research | By Ridker PM, MacFadyen JG, CANTOS Trial Group et al.

BACKGROUND - Canakinumab, a monoclonal antibody targeting interleukin-1β, reduces inflammation and cardiovascular event rates with no effect on lipid concentrations. However, it is uncertain which patient groups benefit the most from treatment and whether reductions in the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) correlate with clinical benefits for individual patients. METHODS - Th...

Mortality Differences Associated With Treatment Responses in CANTOS and FOURIER: Insights and Implications

Expert Opinion | By Ridker PM

Similarities and differences in 2 contemporary postrandomization on-treatment analyses from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) and CANTOS trial (Canakinumab Antiinflammatory Thrombosis Outcome Study) may provide insight into what factors drive reductions in cardiovascular mortality and all-cause mortality among patients with atherosclerosi...

Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis

Review Article | By DK Chu, LH-Y Kim, PJ Young et al.

Background - Supplemental oxygen is often administered liberally to acutely ill adults, but the credibility of the evidence for this practice is unclear. We systematically reviewed the efficacy and safety of liberal versus conservative oxygen therapy in acutely ill adults. Methods - In the Improving Oxygen Therapy in Acute-illness (IOTA) systematic review and meta-analysis, we searched the Cochrane Central Register of Contr...

By Article Type

Original Research 785
Review Article 294
Clinical Case Study 28
Clinical Trial 415
Perspective 9
Guideline 50

By Year

2018 9
2017 1

By Journal

Lancet. 1
Lancet. 3
JAMA Cardiol. 2
JACC Cardiovasc Interv. 1
Circulation. 2
Circ J. 1

Limit By

Title
Content
|<<... 23 24 25 26 27 28 29 ...>>|
↑BACK TO TOP

左主干暨冠状动脉分叉病变峰会

南京市心血管医院丨南京市第一医院丨南京医科大学

长乐路68号丨210006丨中国 · 南京

Copyright ⓒ CBSMD Nanjing China. All rights reserved.

关于境内代表注册有疑问请联系彭红娟、徐海梅老师

+86 - 139 138 954 77 丨 +86 - 139 147 368 46 丨 cbsnj@cbsmd.org

关于境外代表注册有疑问请联系林玲老师

+86 - 139 518 845 96 丨 cbsnj@cbsmd.org

关于学术征集有疑问请联系赵莹莹女士

+86 138 154 085 17 丨 sub@cbsmd.org